{
    "clinical_study": {
        "@rank": "38460", 
        "arm_group": [
            {
                "arm_group_label": "SRI 15mg", 
                "arm_group_type": "Experimental", 
                "description": "DU-176b was orally administered at a dose of 15 mg once daily for 12 weeks."
            }, 
            {
                "arm_group_label": "Normal/MiRI low-dose group", 
                "arm_group_type": "Experimental", 
                "description": "DU-176b was orally administered at a dose of 30 mg once daily for 12 weeks in subjects who had none of the dose adjustment factors (body weight of \u2264 60 kg or the presence of concurrent treatment with quinidine or verapamil). DU-176b was orally administered at a dose of 15 mg once daily for 12 weeks to subjects who had any of the dose adjustment factors, irrespective of the number of dose adjustment factors."
            }, 
            {
                "arm_group_label": "Normal/MiRI high-dose group", 
                "arm_group_type": "Experimental", 
                "description": "DU-176b was orally administered at a dose of 60 mg once daily for 12 weeks in subjects who had none of the dose adjustment factors. DU-176b was orally administered at a dose of 30 mg once daily for 12 weeks to subjects who had any of the dose adjustment factors, irrespective of the number of dose adjustment factors."
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the safety and pharmacokinetics of DU-176b administered to non-valvular atrial\n      fibrillation patients with severe renal impairment, compared with DU-176b administered to\n      non-valvular atrial fibrillation (NVAF) patients with normal renal function or mild renal\n      impairment (Normal/MiRI)."
        }, 
        "brief_title": "Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Non-valvular Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Renal Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with NVAF and SRI, or patients with NVAF and Normal/MiRI.\n\n        Exclusion Criteria:\n\n          -  Patients who are on hemodialysis or patients who may start hemodialysis before the\n             follow-up assessment\n\n          -  Patients who are at a significantly high risk for bleeding\n\n          -  Patients who are receiving treatment with any anticoagulant drugs excluding warfarin,\n             rivaroxaban, and dabigatran\n\n          -  Patients who have evidence of hepatic function test abnormalities"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "93", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01857622", 
            "org_study_id": "DU176b-B-J307"
        }, 
        "intervention": [
            {
                "arm_group_label": "SRI 15mg", 
                "description": "oral DU-176b 15mg once daily", 
                "intervention_name": "DU-176b 15mg", 
                "intervention_type": "Drug", 
                "other_name": "edoxaban"
            }, 
            {
                "arm_group_label": "Normal/MiRI low-dose group", 
                "description": "oral DU-176b 30mg once daily", 
                "intervention_name": "DU-176b 30mg", 
                "intervention_type": "Drug", 
                "other_name": "edoxaban"
            }, 
            {
                "arm_group_label": "Normal/MiRI high-dose group", 
                "description": "oral DU-176b 60mg once daily", 
                "intervention_name": "DU-176b 60mg", 
                "intervention_type": "Drug", 
                "other_name": "edoxaban"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "anticoagulant", 
            "DU-176b", 
            "edoxaban", 
            "factor Xa", 
            "oral", 
            "atrial fibrillation", 
            "severe renal impairment"
        ], 
        "lastchanged_date": "May 16, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan", 
                    "zip": "162-0054"
                }, 
                "name": "Tokyo Women's Medical University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase III Clinical Study of DU-176b (Non-valvular Atrial Fibrillation): Japanese, Multicenter, Open-label Study of DU-176b in Patients With Non-valvular Atrial Fibrillation and Severe Renal Impairment (SRI)", 
        "overall_official": {
            "affiliation": "Osaka National Hospital", 
            "last_name": "Yukihiro Koretsune, Dir", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Incidence of any adjudicated bleeding events (including major bleeding, clinically relevant non-major bleeding, and minor bleeding)", 
                "measure": "Incidence of any adjudicated bleeding events", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Incidence of adverse events", 
                "measure": "Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Incidence of adverse drug reactions", 
                "measure": "Incidence of adverse drug reactions", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Plasma concentration of DU-176b", 
                "measure": "Plasma concentration of DU-176b", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Plasma concentration of D21-2393", 
                "measure": "Plasma concentration of D21-2393", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01857622"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Incidence of adjudicated thromboembolic events (cerebral infarction and systemic embolism)", 
            "measure": "Incidence of adjudicated thromboembolic events (cerebral infarction and systemic embolism)", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "Daiichi Sankyo Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daiichi Sankyo Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}